Back to results
US 2024/0156775 A1Published application
Treatment of circadian rhythm disorders
AssigneeVanda Pharmaceuticals Inc.
InventorsMarlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Claims9
A method of treating a patient suffering from a circadian rhythm disorder, the method comprising internally administering to the patient tasimelteon once daily in an amount effective to shift a free running cortisol circadian rhythm in the patient toward a 24-hour circadian rhythm.
Dependencies are inferred from the claim text.